title: Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.
abstract: OBJECTIVE
  Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes.
  
  
  METHODS
  Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS.
  
  
  RESULTS
  Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05).
  
  
  CONCLUSIONS
  Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.
authors.affiliation: Laboratory of Molecular Pathology, Department of Pathology, Palacky University, Olomouc, Czech Republic. katka.vrzalikova@post.cz
authors.forename: Katerina
authors.initials: K
authors.lastname: Vrzalikova
authors.forename: Joseph
authors.initials: J
authors.lastname: Skarda
authors.forename: Jiri
authors.initials: J
authors.lastname: Ehrmann
authors.forename: Paul G
authors.initials: PG
authors.lastname: Murray
authors.forename: Eduard
authors.initials: E
authors.lastname: Fridman
authors.forename: Jury
authors.initials: J
authors.lastname: Kopolovic
authors.forename: Petra
authors.initials: P
authors.lastname: Knizetova
authors.forename: Marian
authors.initials: M
authors.lastname: Hajduch
authors.forename: Jiri
authors.initials: J
authors.lastname: Klein
authors.forename: Vitezslav
authors.initials: V
authors.lastname: Kolek
authors.forename: Lenka
authors.initials: L
authors.lastname: Radova
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Kolar
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D063150:Polycomb Repressive Complex 1; D011379:Prognosis; D040081:Protein Array Analysis; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism*; D046888:Tissue Array Analysis
chemical_list: C069077:BMI1 protein, human; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D012097:Repressor Proteins; D063150:Polycomb Repressive Complex 1